14th European Meeting on HIV & Hepatitis – Presentations

Wednesday 25 May

HIV in Europe 2020 – what will it look like?
Dr. C. Perno, University of Rome - Tor Vergata, Italy
Session 1: Early ARV treatment: start early, but not too early
Invited lecture: Life-long therapy
Dr. G. Behrens, Medical School Hannover, Germany
 Abstract presentations
 Potent Activity of GS-9883, a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance
Dr. K. White
 Dolutegravir plus Rilpivirine in cART-Experienced Subjects: a cohort study
Dr. G. Sterrantino
 Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects
Dr. G. Sterrantino
Session 2: Spread of HIV drug resistance
 Abstract presentations
 Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population proportions
Dr. R. Ehret
 Transmission of HIV drug resistance mutations varies regionally in Europe
Dr. M. Hofstra
 Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine single tablet regimen
Dr. D. Di Carlo
 Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R
Dr. C. Callebaut
Session 3: Abstract session - HBV- related
HBV cure - Educational lecture in collaboration with ESAR
Dr. M. Levrero, University of Rome - La Sapienza, Italy
 Abstract presentations
 Clinical impact of vaccine-escape HBsAg mutants in HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases
Dr. R. Salpini
 Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death
Dr. A. Battisti
 HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression
Dr. L. Colagrossi
Session 4: Implementation of PrEP in Europe
Roadblocks to implementation
Dr. P. Coll, Irsi Caixa Foundation, Spain
Two cases of HIV drug resistance arising after PrEP 
Dr. R. Harrigan, BC Centre for Excellence in HIV/AIDS, Canada
Community perspective
Dr. R. Webb, EATG, United Kingdom

Thursday 26 May

HIV attachment Inhibitors - Educational lecture in collaboration with ESAR
Dr. T. Klimkait, University of Basel, Switzerland
Session 5: Special session - maintenance therapy
Maintenance Therapy - What is known
Dr. E. Martínez, University of Barcelona, Spain

Maintenance Therapy - What is the scientific/ virological rational
Dr. C. Boucher, Erasmus Medical Center, The Netherlands

Maintenance Therapy - What is the Future
Dr. J. Schapiro, Sheba Medical Center, Israel


Session 1

Host-acting broad-spectrum antiviral drugs from nature
Dr. J. Díez, Universitat Pompeu Fabra, Spain

How do we test for HCV RAV's (technology-based presentation)
Dr. A. Howe, British Columbia Center for Excellence for HIV/AIDS, Canada
 Do we need surveillance for DAA resistance: how to implement it'
Dr. S. Popping, Erasmus Medical Center, The Netherlands
Session 2
What do we know about RAV's today
Dr. F. Ceccherini-Silberstein, University of Rome - Tor Vergata, Italy
 Abstract presentations
 Substantial presence of natural NS3, NS5A and NS5B HCV-resistance in real practice, and their impact on direct-acting antiviral treatment in genotypes 1-4
Dr. V. Cento
 Characterization of Resistance-Associated Variants at baseline and failure of All-Oral Antiviral Therapy of Hepatitis C
Dr. A. Lai
Session 3

What do we need to know about RAV's clinically
Dr. S. Zeuzem, JW Goethe University Hospital, Germany

 Abstract presentations
 Virological failures to DAA in real life show frequent resistance associated variants and may require re-treatment with unconventional regimens
Dr. V.C. Di Maio
 Treatment emergent variants to combined direct antiviral agents therapy against hepatitis C virus
Dr. F. Garcia
 Total HIV DNA increases in lymphomonocytes of HCV/HIV co-infected patients during and after DAA treatment
Dr. I. Abbate

Friday 27 May

Session 6: Remaining challenges in the optimal use of boosted Pis
PI are obsolete in first line
Dr. A. Geretti, University of Liverpool, United Kingdom
PI remain important options for first line
Dr. L. Vandekerckhove, University Hospital Gent, Belgium
Improving PI drug resistance scores
Dr. J. Verheyen, University Clinic Essen, Germany
Session 7: HIV cure strategies
Diagnostic Assays
Dr. J.M. Picado, Irsi Caixa Foundation, Spain
 Abstract presentations
 Ex vivo determination of stem cell transplantation graft-versus-HIV reservoir effects
Dr. L. Hogan
 Clonal Integration Site Frequency and Replication Competent Virus in Patients on ART
Dr. L. Vanderkerckhove
Boston Project
Dr. T. Henrich, UCSF, USA
 Abstract presentations
 Viral dynamics and post-mortem analysis of HIV-1 Reservoir after Allogeneic Transplantation using Stem Cells with a nonfunctional CCR5 (CCR5?32) co-receptor
Dr. K. Bosman
 Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation
Dr. E. Knops
 Breakthrough of preexisting X4-tropic HIV after allogeneic stem-cell transplantation.
Dr. J. Verheyen